If you sell a cream, serum, or shampoo into the U.S. market, the ingredients aren’t what decide whether FDA treats your product as a cosmetic or a drug. The claims you make about it do. This is a very important factor to consider. You could be looking at an unapproved drug on the market, a warning letter, or a shipment held at the port.
This is one of the most common ways international cosmetics brands get tripped up entering the U.S., and it’s easy to miss because the same product, same formula, same packaging, can be perfectly legal as a cosmetic and illegal as an unapproved drug depending only on the marketing copy around it.
The legal test is intended use, not ingredients
Under the Federal Food, Drug, and Cosmetic Act, a cosmetic is something intended to clean, beautify, or alter appearance: moisturizers, lipstick, nail polish, shampoo, makeup, deodorant. A drug is something intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or function of the body.
Notice what’s missing from both definitions: what’s actually in the bottle. FDA determines intended use from your labeling, your website, your ads, and even your ingredient list if an ingredient has a well-known therapeutic use (fluoride in toothpaste is the classic example). Two identical serums can end up in two different regulatory categories purely because one says “smooths the look of fine lines” and the other says “stimulates collagen production to reduce wrinkles.”
Claims that push a cosmetic into drug territory
FDA has flagged specific language patterns that turn a cosmetic claim into a drug claim. Watch for anything that says your product will:
Treat or cure a skin condition, such as acne, eczema, psoriasis, or rosacea. Restore hair growth or prevent hair loss. Reduce cellulite or affect fat metabolism. Treat varicose veins. Increase or decrease melanin production in the skin. Regenerate cells, boost collagen production, or otherwise change the skin’s structure. Provide sun protection (any SPF or “protects from UV damage” claim). Function as an antiperspirant, as opposed to a deodorant. Help with sleep, anxiety, or smoking cessation through “aromatherapy.”
Compare that to language that stays safely in cosmetic territory: “moisturizes,” “improves the appearance of fine lines,” “cleanses,” “adds shine,” “promotes attractiveness.” The difference is between describing a surface-level cosmetic effect and claiming a physiological one.
Some products are legitimately both
This isn’t always a trap to avoid. Plenty of products are intentionally both a cosmetic and a drug, and that’s fine as long as you comply with both sets of requirements. Anti-dandruff shampoo cleanses hair (cosmetic) and treats dandruff (drug). Fluoride toothpaste cleans teeth (cosmetic) and fights cavities (drug). Moisturizer with SPF beautifies skin (cosmetic) and prevents sunburn (drug).
If your product falls into this category, the active drug ingredient has to come from an FDA over-the-counter monograph, which lists the ingredients and conditions FDA has already found generally recognized as safe and effective for a given use. Acne treatments, dandruff/psoriasis treatments, and sunscreens are the three monograph categories cosmetics companies run into most often. If your ingredient and claim fit a monograph, you can market it as an OTC drug without a full New Drug Application. If it doesn’t, you generally need FDA approval before you can sell it, which most cosmetics companies aren’t set up for.
Anti-aging is the trap here. There is no FDA monograph for anti-aging or anti-wrinkle products. That means any product making a structural anti-aging claim (“stimulates cell renewal,” “rebuilds collagen”) isn’t covered by a shortcut. It would need full drug approval, which almost nobody selling a $40 serum has. This is exactly why so many skincare brands keep anti-aging language limited to appearance (“visibly reduces the look of fine lines”) rather than mechanism.
Why this matters more than a labeling tweak
A cosmetic marketed with drug claims but without drug approval is, legally, an unapproved new drug. That’s a different and more serious problem than a mislabeled cosmetic. Consequences can include FDA warning letters, product seizure, import refusal at the border, and in repeat or serious cases, injunctions. If you’re a foreign manufacturer, your U.S. Agent is FDA’s point of contact when a compliance issue like this comes up, which means unclear or aggressive marketing claims can turn into a problem your agent has to help you manage in real time.
The other consequence importers underestimate: once a product is classified as a drug, it needs drug establishment registration, drug listing, and Drug Facts labeling under 21 CFR 201.66, none of which is the same process as MoCRA cosmetic facility registration and product listing. Brands that don’t realize their claims moved them into drug territory often find out when their shipment gets held or their listing gets flagged, not before.
A practical check before you finalize labels or ad copy
Before your product ships or your marketing goes live, run every claim through one question: am I describing how this changes the way the product looks, or how it changes the way the body works? Appearance claims stay in cosmetic territory. Function, structure, or disease claims move you into drug territory, whether or not you intended that.
If you’re marketing internationally and translating claims into English for the U.S. market, this is worth a second look specifically. Claims that are standard, even required, cosmetic marketing language in the EU or Asia sometimes read as drug claims under FDA’s definitions. What’s compliant in your home market isn’t automatically compliant here.
If you’re not sure whether your claims put you in cosmetic or OTC drug territory, or your U.S. Agent needs to be someone who can flag this before it becomes a compliance problem, FDA Entry can help you sort it out before your product hits the U.S. market.
FAQs
FDA looks at intended use, not what’s in the formula. Intended use comes from your labeling, website, ads, and social media, and sometimes from an ingredient with a well-known therapeutic use, like fluoride in toothpaste. Two products with identical ingredients can land in different categories depending only on how you describe what they do.
Yes, and it’s common. Anti-dandruff shampoo, fluoride toothpaste, and moisturizer with SPF are all cosmetic/drug combinations: they clean or beautify (cosmetic function) and also treat or prevent a condition (drug function). If your product fits this pattern, the drug portion has to follow an FDA over-the-counter monograph or go through full drug approval, and you’re required to meet the labeling and registration rules for both categories, not just one.
You can describe appearance. You can’t describe mechanism. “Reduces the look of fine lines” is a cosmetic claim because it’s about how skin looks. “Boosts collagen production” or “regenerates cells” is a drug claim because it describes a structural change to the body, and FDA has no monograph for anti-aging or anti-wrinkle products. Without a monograph to fall back on, that claim would need full FDA drug approval, which almost no skincare brand has.
It becomes a compliance problem, not just a labeling one. FDA can issue a warning letter, refuse the product entry at a U.S. port, or in serious or repeated cases pursue seizure or an injunction. It also means the product needs drug establishment registration, drug listing, and Drug Facts labeling under 21 CFR 201.66, an entirely different process than MoCRA cosmetic facility registration and product listing. Most brands find out the hard way, when a shipment gets held or a listing gets flagged.